FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206626386> ?p ?o ?g. }

• W4206626386 endingPage "61" @default.
• W4206626386 startingPage "49" @default.
• W4206626386 abstract "The continued rise in the availability of illicit opioids and opioid-related deaths in the United States has left physicians, researchers, and lawmakers desperate for solutions to this ongoing epidemic. The research into therapeutic options for the treatment of opioid use disorder (OUD) began with the introduction of methadone in the 1960s. The approval of oral naltrexone initially showed much promise, as the drug was observed to be highly potent in antagonizing the effects of opioids while producing no opioid agonist effects of its own and having a favorable side effect profile. Patients that routinely take their naltrexone reported fewer days of heroin use and had more negative drug tests than those without treatment. Poor outcomes in OUD patients treated with naltrexone have been directly tied to short treatment time. Studies have shown that naltrexone given orally vs. as an implant at the 6-month interval showed a higher non-compliance rate among those who used oral medications at the 6-month mark and a slower return to use rate. There were concerns that naltrexone could possibly worsen negative symptoms seen in opiate use disorder related to blockade of endogenous opioids that are important for pleasurable stimuli. Studies have shown that naltrexone demonstrated no increase in levels of anxiety, depression and anhedonia in participants and another study found that those treated with naltrexone had a significant reduction in mental health-related hospitalizations. The latter study also concluded that there was no increased risk for mental health-related incidents in patients taking naltrexone via a long-acting implant. Although not yet FDA approved in the United States, naltrexone implant has shown promising results in Europe and Australia and may provide a novel treatment option for opioid addiction." @default.
• W4206626386 created "2022-01-25" @default.
• W4206626386 creator A5003576927 @default.
• W4206626386 creator A5007412928 @default.
• W4206626386 creator A5009464042 @default.
• W4206626386 creator A5018558604 @default.
• W4206626386 creator A5031257434 @default.
• W4206626386 creator A5050153539 @default.
• W4206626386 creator A5060682188 @default.
• W4206626386 creator A5078679898 @default.
• W4206626386 creator A5087345721 @default.
• W4206626386 creator A5089503803 @default.
• W4206626386 creator A5089954811 @default.
• W4206626386 date "2021-12-30" @default.
• W4206626386 modified "2023-10-16" @default.
• W4206626386 title "Naltrexone Implant for Opioid Use Disorder" @default.
• W4206626386 cites W122479780 @default.
• W4206626386 cites W1489894199 @default.
• W4206626386 cites W195764198 @default.
• W4206626386 cites W1978193643 @default.
• W4206626386 cites W1985094131 @default.
• W4206626386 cites W1990391721 @default.
• W4206626386 cites W1996385835 @default.
• W4206626386 cites W1997980357 @default.
• W4206626386 cites W2002469502 @default.
• W4206626386 cites W2008859660 @default.
• W4206626386 cites W2010510682 @default.
• W4206626386 cites W2011297677 @default.
• W4206626386 cites W2047496048 @default.
• W4206626386 cites W2060990337 @default.
• W4206626386 cites W2065068177 @default.
• W4206626386 cites W2074570011 @default.
• W4206626386 cites W2079048853 @default.
• W4206626386 cites W2088639396 @default.
• W4206626386 cites W2093248443 @default.
• W4206626386 cites W2144969275 @default.
• W4206626386 cites W2145366493 @default.
• W4206626386 cites W2167105661 @default.
• W4206626386 cites W2171008207 @default.
• W4206626386 cites W2331724816 @default.
• W4206626386 cites W2418750714 @default.
• W4206626386 cites W2476733853 @default.
• W4206626386 cites W2561135550 @default.
• W4206626386 cites W2604216606 @default.
• W4206626386 cites W2800072530 @default.
• W4206626386 cites W2811399045 @default.
• W4206626386 cites W2906914546 @default.
• W4206626386 cites W3012261821 @default.
• W4206626386 doi "https://doi.org/10.3390/neurolint14010004" @default.
• W4206626386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35076607" @default.
• W4206626386 hasPublicationYear "2021" @default.
• W4206626386 type Work @default.
• W4206626386 citedByCount "8" @default.
• W4206626386 countsByYear W42066263862022 @default.
• W4206626386 countsByYear W42066263862023 @default.
• W4206626386 crossrefType "journal-article" @default.
• W4206626386 hasAuthorship W4206626386A5003576927 @default.
• W4206626386 hasAuthorship W4206626386A5007412928 @default.
• W4206626386 hasAuthorship W4206626386A5009464042 @default.
• W4206626386 hasAuthorship W4206626386A5018558604 @default.
• W4206626386 hasAuthorship W4206626386A5031257434 @default.
• W4206626386 hasAuthorship W4206626386A5050153539 @default.
• W4206626386 hasAuthorship W4206626386A5060682188 @default.
• W4206626386 hasAuthorship W4206626386A5078679898 @default.
• W4206626386 hasAuthorship W4206626386A5087345721 @default.
• W4206626386 hasAuthorship W4206626386A5089503803 @default.
• W4206626386 hasAuthorship W4206626386A5089954811 @default.
• W4206626386 hasBestOaLocation W42066263861 @default.
• W4206626386 hasConcept C118552586 @default.
• W4206626386 hasConcept C126322002 @default.
• W4206626386 hasConcept C170493617 @default.
• W4206626386 hasConcept C2777972943 @default.
• W4206626386 hasConcept C2778767360 @default.
• W4206626386 hasConcept C2778903686 @default.
• W4206626386 hasConcept C2779418921 @default.
• W4206626386 hasConcept C2780035454 @default.
• W4206626386 hasConcept C2781063702 @default.
• W4206626386 hasConcept C3019590667 @default.
• W4206626386 hasConcept C42219234 @default.
• W4206626386 hasConcept C558461103 @default.
• W4206626386 hasConcept C71924100 @default.
• W4206626386 hasConceptScore W4206626386C118552586 @default.
• W4206626386 hasConceptScore W4206626386C126322002 @default.
• W4206626386 hasConceptScore W4206626386C170493617 @default.
• W4206626386 hasConceptScore W4206626386C2777972943 @default.
• W4206626386 hasConceptScore W4206626386C2778767360 @default.
• W4206626386 hasConceptScore W4206626386C2778903686 @default.
• W4206626386 hasConceptScore W4206626386C2779418921 @default.
• W4206626386 hasConceptScore W4206626386C2780035454 @default.
• W4206626386 hasConceptScore W4206626386C2781063702 @default.
• W4206626386 hasConceptScore W4206626386C3019590667 @default.
• W4206626386 hasConceptScore W4206626386C42219234 @default.
• W4206626386 hasConceptScore W4206626386C558461103 @default.
• W4206626386 hasConceptScore W4206626386C71924100 @default.
• W4206626386 hasIssue "1" @default.
• W4206626386 hasLocation W42066263861 @default.
• W4206626386 hasLocation W42066263862 @default.
• W4206626386 hasLocation W42066263863 @default.

• next